BEAMSTART Logo

Samsung Biologics signs initial deal with LigaChem Bio on ADC production

Korea Economic Daily LogoKorea Economic Daily6d ago

Samsung Biologics signs initial deal with LigaChem Bio on ADC production - Korea Economic Daily

Quick Summary:

Through its latest deal with Samsung, the biotech startup is expected to expand its production using domestic facilities, industry officials said.“Through aggressive R&D investment, we aim to build more than 15 clinical pipelines within the next five years,” said LigaChem Chief Executive Kim Yong-zu.“We will closely work with Samsung to develop new drugs.” SAMSUNG’S ADC PROJECTSLast year, Samsung Biologics completed a dedicated ADC production plant in Songdo, Incheon – a four-story building with a 500-liter conjugation reactor and one purification line.“We are happy to work with LigaChem to provide high-quality ADC therapeutics to patients,” said John Rim, chief executive of Samsung Biologics.

Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences Inc., a South Korean biotech startup, to jointly develop and produce antibody-drug conjugate (ADC) products.

CLOSER TIES BETWEEN SAMSUNG, LIGACHEM BIOThe memorandum of understanding on their ADC collaboration comes after Samsung last year signed a contract development (CDO) agreement and a material transfer agreement (MTA) with LigaChem, formerly known as LegoChem Biosciences.


More Pictures

Samsung Biologics signs initial deal with LigaChem Bio on ADC production - Korea Economic Daily (Picture 1)Samsung Biologics signs initial deal with LigaChem Bio on ADC production - Korea Economic Daily (Picture 2)Samsung Biologics signs initial deal with LigaChem Bio on ADC production - Korea Economic Daily (Picture 3)Samsung Biologics signs initial deal with LigaChem Bio on ADC production - Korea Economic Daily (Picture 4)

or

Article Details

Category: Economy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-09 @ 19:30:59 (6 days ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 439 words

Reading Time: 3 minutes read

Sentences: 24 lines

Sentence Length: 19 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 25171498

View Article Analysis

About Korea Economic Daily

Korea Economic Daily Logo

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 7 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 3 hours ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Samsung Biologics signs initial deal with LigaChem Bio on ADC production" has 439 words across 24 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Which news outlet covered this story?

The story "Samsung Biologics signs initial deal with LigaChem Bio on ADC production" was covered 6 days ago by Korea Economic Daily, a news publisher based in South Korea.

How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.

The outlet is headquartered in South Korea and publishes an average of 7 news stories per day.

It's most recent story was published 3 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Positive, indicating that people regard this as "good news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #25171498
  • URL: https://beamstart.com/news/samsung-biologics-signs-initial-deal-1736927954910

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.